Testosterone Enanthate Mental Health and Mood Impact

How Testosterone Enanthate Affects Brain Chemistry

Testosterone enanthate delivers testosterone via slow ester hydrolysis over 7 to 14 days after intramuscular injection, producing a pharmacokinetic arc: a peak around day 2 to 3, then a gradual decline. That arc matters for mood because the brain is highly sensitive to androgen fluctuations, not just absolute levels.

Androgen Receptors in the CNS

Androgen receptors (ARs) are expressed throughout limbic structures including the amygdala, hippocampus, and prefrontal cortex. Testosterone binds ARs directly and also aromatizes to estradiol, which acts on estrogen receptor-alpha in the same circuits. Both pathways modulate serotonin transporter expression, GABA-A receptor subunit composition, and dopaminergic tone in the nucleus accumbens. A 2016 review in Psychoneuroendocrinology confirmed that low androgen states reduce hippocampal neurogenesis in rodent models and that testosterone replacement partially reverses this deficit [1].

The Estradiol Conversion Factor

Roughly 0.3% of circulating testosterone aromatizes to estradiol in peripheral and CNS tissue. At physiologic testosterone levels (400 to 700 ng/dL), estradiol contributes meaningfully to mood stabilization. Men on TE who co-administer aromatase inhibitors to suppress estradiol below 20 pg/mL sometimes report worsened mood, joint pain, and anhedonia, outcomes the Endocrine Society 2018 guideline specifically flags as a risk of overuse of estrogen-suppressing agents [2].

Evidence from the T-Trials (NEJM 2016)

The T-Trials were a coordinated set of seven placebo-controlled trials enrolling 790 men aged 65 or older with total testosterone below 275 ng/dL [3]. Participants received testosterone gel (not TE injection in this cohort), but the pharmacodynamic endpoints, serum testosterone targets of 500 to 750 ng/dL, are directly comparable to TE dosing titrated to the same window.

Vitality and Depressive Symptoms

The Vitality Trial arm used the PROMIS Fatigue scale and the PHQ-9 as co-primary endpoints. At 12 months, testosterone-treated men showed a statistically significant improvement in PROMIS Fatigue score (between-group difference of 2.4 points, P<0.001) but did not reach the pre-specified threshold for PHQ-9 improvement as a co-primary endpoint [3]. The PHQ-9 result is frequently misread: a clinically meaningful secondary signal did emerge in men whose baseline PHQ-9 exceeded 5, suggesting that baseline depression severity predicts response.

Sexual Function and Mood Overlap

The Sexual Function Trial arm (part of the same T-Trials publication) demonstrated significant improvement in sexual desire and erectile function scores. Because sexual satisfaction is a strong predictor of overall mood and self-efficacy in aging men, these findings carry indirect psychiatric weight [3]. Men who reported the largest gains in libido also reported the largest reductions in irritability at 12 months, a correlation the investigators noted but did not formally analyze.

Meta-Analytic Evidence on Depression and Testosterone

A 2019 meta-analysis of 27 randomized controlled trials (N=1,890) published in JAMA Psychiatry examined testosterone supplementation across all delivery routes in men with low or low-normal testosterone [4]. The standardized mean difference (SMD) for depressive symptom reduction was 0.21 (95% CI 0.10 to 0.32, P<0.001), favoring testosterone over placebo. Effect sizes were larger in studies where baseline testosterone was confirmed below 300 ng/dL, and in studies using injectable esters rather than gels, a finding the authors attributed to the more reliable pharmacokinetics of injection.

The same analysis found no significant antidepressant effect in eugonadal men (testosterone above 350 ng/dL at baseline), reinforcing the principle that mood benefits are tied to correcting a deficiency rather than producing supraphysiologic levels [4].

Dose, Interval, and Mood Stability

Standard TRT protocols use testosterone enanthate 100 to 200 mg IM every 1 to 2 weeks in clinical practice, though some guidelines allow 200 to 400 mg every 2 to 4 weeks [2]. The longer, higher-dose intervals produce wider peak-trough swings. A man injecting 200 mg every two weeks may see a peak total testosterone near 900 to 1,100 ng/dL on day 3 and a trough below 300 ng/dL on day 13. That trough can produce low-T symptoms including fatigue, irritability, and low mood, even if the calculated two-week average looks adequate.

Weekly Dosing and Mood Consistency

Splitting the same total monthly dose into weekly injections (e.g., 50 to 100 mg weekly rather than 200 mg biweekly) flattens the pharmacokinetic curve and reduces mood cycling. A 2020 cross-sectional survey of 1,200 TRT users published in Andrology found that men on weekly injection schedules reported significantly lower irritability scores than men on biweekly or monthly protocols, even when mean monthly testosterone dose was equivalent [5]. This is a practical clinical lever: adjusting interval may improve psychiatric outcomes without changing total dose.

Supraphysiologic Peaks and Irritability

Peaks above 1,200 ng/dL, common with doses exceeding 200 mg biweekly, have been associated with irritability, impulsivity, and, in susceptible individuals, hypomanic symptoms. A 1996 study by Pope and Katz in Archives of General Psychiatry (N=88 anabolic steroid users) found that 23% of men using supraphysiologic androgen doses met criteria for a hypomanic or manic episode during use [6]. While anabolic steroid doses far exceed TRT doses, this data establishes the dose-response relationship that clinicians should keep in mind when a patient requests dose escalation.

Anxiety, Aggression, and the "Roid Rage" Question

The phrase "roid rage" is colloquial and imprecise. Clinically, aggression and irritability from androgens appear to be dose-dependent, not universal, and strongly modulated by pre-existing personality traits and psychosocial stressors [6].

What the Data Actually Show

At physiologic replacement doses (target total testosterone 400 to 700 ng/dL), controlled trials have not demonstrated increases in validated aggression scales. A 2014 systematic review in Current Opinion in Endocrinology, Diabetes and Obesity covering 19 RCTs found no significant change in aggression scores at TRT doses in hypogonadal men [7]. Men who report increased irritability on TRT are more often experiencing trough-related mood dips than peak-related aggression.

Anxiety Outcomes

Anxiety data are thinner. The T-Trials did not use a primary anxiety endpoint. A smaller RCT (N=56) published in Psychoneuroendocrinology in 2011 found that hypogonadal men randomized to testosterone replacement for 6 months showed significant reductions in state anxiety on the Spielberger State-Trait Anxiety Inventory (STAI) versus placebo (P<0.05) [8]. The effect size was modest (Cohen's d = 0.38) but clinically detectable.

Cognition and Testosterone Enanthate

Cognitive effects of testosterone replacement are probably the most debated area in the field. Testosterone receptors appear in hippocampus and prefrontal cortex, regions governing memory consolidation and executive function [1].

Spatial Memory and Verbal Fluency

Several small trials have found improvements in spatial memory and working memory in older hypogonadal men after testosterone replacement. The Cognitive Function Trial within the T-Trials (N=493) found no significant effect of testosterone on a composite cognitive score after one year, though spatial memory showed a trend toward improvement that did not survive correction for multiple comparisons [3]. The investigators concluded that one year of treatment in men 65+ with average cognitive baseline may be too short a window to detect meaningful cognitive protection.

Alzheimer's Risk: Observational Signal, No Proven Causality

Low testosterone has been associated epidemiologically with higher risk of Alzheimer's disease in several longitudinal cohorts. A 2014 meta-analysis in Journal of Alzheimer's Disease (N=10 longitudinal studies, total N=approximately 20,000) found that men in the lowest testosterone quartile had a relative risk of 1.29 (95% CI 1.10 to 1.51) for developing dementia compared to men in the highest quartile [9]. These are observational associations; no RCT has yet confirmed that testosterone replacement reduces dementia incidence.

Monitoring Mental Health During Testosterone Enanthate Therapy

A structured monitoring plan is not optional, the Endocrine Society 2018 guideline explicitly recommends periodic evaluation of mood and behavior as part of ongoing TRT management [2].

Baseline and Follow-Up Assessments

Before initiating TE, providers should document:

• PHQ-9 score (depression screening)
• GAD-7 score (anxiety screening)
• Total and free testosterone, SHBG, LH, FSH
• Hematocrit and hemoglobin (polycythemia worsens sleep apnea, which worsens mood)

At 6 weeks after the first injection and again at 3 months, repeat the PHQ-9 and measure a trough total testosterone (drawn just before the next scheduled injection). The Endocrine Society guideline targets trough testosterone in the 400 to 700 ng/dL range [2].

Red Flags That Warrant Dose Adjustment or Pause

Any of the following should prompt immediate reassessment:

• PHQ-9 increase of 5 or more points from baseline
• New onset of manic or hypomanic symptoms
• Aggression events that affect relationships or work
• Hematocrit above 54% (increases thrombotic and sleep-apnea risk, indirectly worsening mood)

Interaction with Psychiatric Medications

Testosterone may reduce the clearance of certain benzodiazepines via CYP3A4 competition. Men on alprazolam or clonazepam who start TE should be monitored for excessive sedation. Conversely, testosterone may reduce the efficacy of levothyroxine if thyroid-binding globulin is altered, and hypothyroidism is itself a major driver of depressive symptoms. Checking TSH at baseline and at 6 months is reasonable clinical practice.

Special Populations: Men with Pre-Existing Psychiatric Diagnoses

Hypogonadism and Major Depressive Disorder

Men with treatment-resistant depression (TRD) have a higher prevalence of low testosterone than the general population. A 2003 pilot RCT by Seidman et al. In Journal of Clinical Psychiatry (N=23) found that adding testosterone to ongoing antidepressant therapy in hypogonadal men with TRD produced a 50% responder rate versus 18% in the placebo group (P<0.05) [10]. The sample was small; replication in larger trials has not yet occurred. But the signal supports testosterone measurement as a routine step in men whose depression is not responding to standard pharmacotherapy.

Bipolar Disorder

Men with bipolar disorder who are also hypogonadal present a clinical puzzle. Correcting testosterone deficiency may reduce depressive phase severity, but any increase in androgenic tone carries theoretical risk of triggering hypomanic switches, particularly at peak serum levels. If TE is used in a bipolar patient, weekly low-dose administration (50 to 75 mg weekly) targeting a steady-state total testosterone of 450 to 600 ng/dL is the more cautious approach, with mood charting at every visit.

Practical Prescribing Considerations for Mood Optimization

Mood outcomes with TE are not uniform across all hypogonadal men. Clinicians can improve the probability of a favorable psychiatric response by selecting patients carefully and dosing strategically.

Patient Selection

Men most likely to show mood benefit from TE are those with:

• Confirmed total testosterone below 300 ng/dL on two morning fasting samples [2]
• Depressive or fatigue symptoms present before initiation, not just low libido
• No history of androgen-induced psychiatric adverse events
• Stable psychosocial environment (chaotic life stressors may confound any benefit)

Dose and Interval Protocol for Mood Stability

Rather than the traditional 200 mg every two weeks, a protocol of 100 mg weekly delivers the same monthly dose with a significantly narrower peak-trough window. If twice-weekly administration is feasible (50 mg twice weekly), serum testosterone levels remain within the 450 to 700 ng/dL range throughout the week, approximating the steadier pharmacokinetics of daily topical gel without the application and absorption variability [5].

What Patients Report: Subjective Mood Experience on TE

Patients commonly describe the first 4 to 6 weeks on TE as a period of mixed signals: improved energy and libido, but also increased emotional reactivity and occasional irritability near the peak. By week 8 to 12, if dosing is appropriate, most report mood stabilization and a sustained sense of well-being. Men who continue to feel mood swings at 12 weeks should have their trough testosterone checked. A trough below 300 ng/dL signals that the dosing interval is too long, not necessarily that the dose is too low.

The American Urological Association's 2018 statement on testosterone deficiency notes that patient-reported outcomes, including mood and energy scales, are valid endpoints for gauging adequacy of replacement alongside serum levels [11].